LONDON (ShareCast) - (Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.
The AIM and Nasdaq-traded firm said it was an investigator-initiated study, led by professor Thomas Powles, lead for solid tumour research at Barts Cancer Institute, and sponsored by Queen Mary University of London.

"Full data from the PRCC cohort of the CALYPSO study will be presented on 15 February, in oral and poster presentations at the annual American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco," the board said in its statement.

Chi-Med noted that preliminary results of the study were first presented on 16 February 2019 at the same symposium.

It described PRCC as a subtype of kidney cancer, that was "unusually difficult" to treat, with low response rates from current treatment options and no treatments approved for the specific indication.

"The CALYPSO study is an independently sponsored open-label phase 2 study of Imfinzi in combination with several drug candidates in the treatment of renal cell carcinoma in the UK and Spain," the board said.

"Several arms of CALYPSO are evaluating the treatment of PRCC and clear cell renal carcinoma (ccRCC) with savolitinib, a highly selective inhibitor of the MET receptor tyrosine kinase, both as a monotherapy and in combination with Imfinzi - AstraZeneca's anti-programmed death-ligand 1 (PD-L1) antibody.

"CALYPSO enrolls an all-comer PRCC population with planned retrospective molecular profiling."

At 1501 GMT, shares in Hutchison China MediTech were up 3.5% in London at 414p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE